|
|
GLA-Alum |
|
Vaxjo ID |
161 |
|
Vaccine Adjuvant Name |
GLA-Alum |
|
Adjuvant VO ID |
VO_0006099
|
|
Description |
A combination vaccine adjuvant of a synthetic TLR agonist and aluminum salt that induces a Th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
Aluminum hydroxide with TLR-4 agonist (GLA) and dipalmitoyl phosphatidylcholine |
|
Storage |
2-8C |
|
Function |
innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=83]
Tamborrini et al., 2023: Tamborrini M, Schäfer A, Hauser J, Zou L, Paris DH, Pluschke G. The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals. Malaria journal. 2023; 22(1); 210. [PubMed: 37454145].
|
|
